Strasser S I, Watson K J, Lee C S, Coghlan P J, Desmond P V
Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC.
Med J Aust. 1995 Apr 3;162(7):355-8.
To define demographic and epidemiological features of an Australian population with chronic hepatitis C virus (HCV) infection and determine predictors of histological and clinical outcome.
Cohort study.
342 consecutive HCV antibody-positive patients referred to the liver clinic of a major metropolitan general hospital.
Demographic data, serial alanine aminotransferase (ALT) levels, full blood count for all patients. Percutaneous liver biopsy in 152 patients (44%).
51% of patients had previously used injecting drugs, 15% had received a blood transfusion and 27% had no definite percutaneous risk factor (sporadic group). The injecting drug users (IDUs) were younger and more likely to have been born in Australia. The sporadic group were older and frequently were born in Mediterranean or Asian countries. A history of excessive alcohol use was common, particularly among IDUs (60%). Of 152 patients who had a liver biopsy, 49 had cirrhosis and 103 had chronic hepatitis. Some patients with a normal ALT level had marked necro-inflammatory activity. On univariate analysis, the presence of cirrhosis correlated with older age (P < 0.0001), lack of an identifiable risk factor (P < 0.001) and birth in a Mediterranean or Asian country (P < 0.0001). On multivariate analysis, the only significant predictor of cirrhosis was age (P < 0.001). Among patients with an identifiable percutaneous risk factor, cirrhosis was seen at a median time of 18 years after first exposure to risk, compared with 13 years in patients with chronic hepatitis (P < 0.01). Patients with clinical evidence of portal hypertension were, on average, 15 years older than those with histological cirrhosis only (P < 0.01).
Injecting drug use is the major risk factor for chronic HCV infection in Australia. In patients with an identifiable risk factor, the most significant factor associated with a biopsy finding of cirrhosis is the time since first exposure to HCV.
明确澳大利亚慢性丙型肝炎病毒(HCV)感染人群的人口统计学和流行病学特征,并确定组织学和临床结局的预测因素。
队列研究。
342例连续转诊至一家大型都市综合医院肝病门诊的HCV抗体阳性患者。
所有患者的人口统计学数据、系列丙氨酸氨基转移酶(ALT)水平、全血细胞计数。152例患者(44%)接受经皮肝活检。
51%的患者既往有注射吸毒史,15%曾接受输血,27%无明确的经皮危险因素(散发病例组)。注射吸毒者(IDU)较年轻,且更有可能出生在澳大利亚。散发病例组年龄较大,常出生于地中海或亚洲国家。过量饮酒史很常见,尤其是在注射吸毒者中(60%)。在152例接受肝活检的患者中,49例有肝硬化,103例有慢性肝炎。一些ALT水平正常的患者有明显的坏死性炎症活动。单因素分析显示,肝硬化的存在与年龄较大(P<0.0001)、缺乏可识别的危险因素(P<0.001)以及出生于地中海或亚洲国家(P<0.0001)相关。多因素分析显示,肝硬化的唯一显著预测因素是年龄(P<0.001)。在有可识别经皮危险因素的患者中,首次接触危险因素后出现肝硬化的中位时间为18年,而慢性肝炎患者为13年(P<0.01)。有门静脉高压临床证据的患者平均比仅组织学诊断为肝硬化的患者大15岁(P<0.01)。
在澳大利亚,注射吸毒是慢性HCV感染的主要危险因素。在有可识别危险因素的患者中,与活检发现肝硬化相关的最显著因素是首次接触HCV后的时间。